Renalytix PLC
08 September 2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
8 September 2026
Renalytix Plc
("Renalytix" or the "Company")
Result of WRAP Retail Offer
Renalytix is pleased to announce, further to its announcement of 3 September 2026, the completion of the WRAP Retail Offer at an issue price of £0.06 per Ordinary Share (the "Placing Price"). Pursuant to the WRAP Retail Offer, the Company has raised aggregate gross proceeds of £380,142.12, in addition to the £10.1 million gross proceeds raised through the Placing and Subscription, which was previously announced at 7.00 a.m. on 3 September 2026. Accordingly, the Company proposes to allot and issue a total of 6,335,707 Retail Offer Shares, subject to the passing of certain resolutions at the General Meeting.
In addition, and further to the Company's announcement dated 3 September 2026, VenHedge Capital Partners, LP ("VenHedge") has amended its total subscription amount to US$2.25 million (being £1,661,988) as one of its LPs, Feynman Point Asset Management Master Fund Ltd ("Feynman"), has decided to participate in the Subscription at a total amount of $500,000 (being £369,331) directly rather than via VenHedge. VenHedge have entered into an updated subscription agreement to reflect a total subscription of US$2.25 million (being £1,661,988), whilst Feynman have provided the Company with a subscription agreement to reflect a total subscription of $500,000 (being £369,331). The total subscription amount from VenHedge and its associated parties remains US$2.75 million (being £2,031,319).
In total, the Placing, the Subscription and the WRAP Retail Offer have raised gross proceeds of approximately £10.5 million for the Company, of which £3.9 million is conditional upon the passing of certain resolutions at the General Meeting.
For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the Retail Offer Shares (and the Second Tranche Placing Shares and the Subscription Shares) is conditional upon, inter alia:
|
● |
the passing of certain resolutions to be put to shareholders of the Company at the General Meeting, which is expected to be held at 1 Bow Churchyard, London EC4M 9DQ at 12.00 p.m. on 28 September 2026; and |
|
● |
the First Tranche Placing Shares, Conversion Shares, Second Tranche Placing Shares, Subscription Shares and Retail Offer Shares being admitted to trading on AIM. |
It is anticipated that First Admission will become effective and that dealings in the First Tranche Placing Shares and the Conversion Shares will commence on AIM at 8.00 a.m. today. It is anticipated that Second Admission is expected to become effective with dealings in the Retail Offer Shares, the Second Tranche Placing Shares and the Subscription Shares will commence on AIM at 8.00 a.m. on 29 September 2026 (subject to the passing of the resolutions at the General Meeting).
Second Tranche of the Fundraise
The second tranche of the Fundraise, which will be subject to shareholder approval at the General Meeting, will consist of the issue of 7,500,000 Second Tranche Placing Shares, 52,792,950 Subscription Shares and 6,335,707 Retail Offer Shares, totalling 66,628,657 Ordinary Shares.
Close of Capital Access Window and Resumption of Trading
Following completion of the WRAP Retail Offer, the Company confirms that the Capital Access Window, which commenced at 7.45 am on 1 September 2026, has now closed.
Accordingly, the Company's existing Ordinary Shares are expected to resume trading on AIM at 7.30 am today alongside the admission of the 166,811,996 First Tranche Shares, comprising 109,082,255 First Tranche Placing Shares and 57,729,741 Conversion Shares.
Terms used but not defined in this announcement have the same meaning as set out in the Company's 'Result of Fundraise' announcement released at 7.00 a.m. on 3 September 2026.
|
Renalytix plc |
||
|
James McCullough, CEO Julian Baines, Chair |
Via Walbrook PR |
|
|
|
||
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke / Vadim Alexandre |
||
|
Oberon Capital (Joint Broker and Sole Bookrunner) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering / Heena Karani |
||
|
Winterflood Retail Access Platform |
WRAP@winterflood.com |
|
|
Sophia Bechev, Kaitlan Billings |
Tel: +44 (0)20 3100 0214 |
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
Further information on the Company can be found on its website at www.renalytix.com
The Company's LEI is 213800NTOH3FK3WER551
This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.
Important Notices
The release, publication or distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction. This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Ordinary Shares in any such jurisdiction.
This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.
WRAP is a proprietary technology platform owned and operated by Marex Financial ("MF"). MF is incorporated under the laws of England and Wales (company no. 5613061, LEI no. 5493003EETVWYSIJ5A20 and VAT registration no. GB 872 8106 13) and is authorised and regulated by the Financial Conduct Authority (FCA registration number 442767). MF's registered address is at 155 Bishopsgate, London, EC2M 3TQMF is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the WRAP Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the WRAP Retail Offer, Admission and the other arrangements referred to in this announcement.
The value of the new Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.
Certain statements in this announcement may constitute forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.
These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company and MF expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the FCA, the London Stock Exchange or applicable law.
The information in this announcement is for background purposes only and does not purport to be full or complete. Neither MF nor any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. MF and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.
Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Ordinary Shares to be issued or sold pursuant to the WRAP Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.
SP Angel Corporate Finance LLP (the "Nominated Adviser") is authorised and regulated by the FCA in the United Kingdom and is acting as nominated adviser to the Company in connection with the Placing. The Nominated Adviser has not authorised the contents of, or any part of, this announcement, and no liability whatsoever is accepted by the Nominated Adviser for the accuracy of any information or opinions contained in this announcement or for the omission of any material information. The responsibilities of the Nominated Adviser as the Company's Nominated Adviser under the Market Rules for Companies and the Market Rules for Nominated Advisers are owed solely to London Stock Exchange plc and are not owed to the Company or to any director or shareholder of the Company or any other person, in respect of its decision to acquire shares in the capital of the Company in reliance on any part of this announcement, or otherwise.
Oberon Investments Limited t/a Oberon Capital (the "Broker") is authorised and regulated by the FCA in the United Kingdom. The Broker is acting solely as broker and bookrunner exclusively for the Company and no one else in connection with the Placing and the contents of this Announcement and will not regard any other person (whether or not a recipient of this Announcement) as its client in relation to the Placing or the contents of this Announcement nor will it be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the contents of this Announcement. Apart from the responsibilities and liabilities, if any, which may be imposed on the Broker by FSMA or the regulatory regime established thereunder, the Broker accepts no responsibility whatsoever, and makes no representation or warranty, express or implied, for the Placing or the contents of this Announcement including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on behalf of it, the Company or any other person, in connection with the Company and the contents of this Announcement, whether as to the past or the future. The Broker accordingly disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise (save as referred to above), which it might otherwise have in respect of the contents of this Announcement or any such statement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.